top of page

Modifying the Function of Receptors that Drive Inflammatory Disease

THE SCIENCE

A new class of anti-inflammatory drugs that modify Protease-Activated Receptor signaling (PARmodulins)

Parmodulins are small molecules that can selectively block certain aspects of inflammation while promoting anti-inflammatory signals mediated by protease-activated receptor 1 (PAR1).

PAR1 + vorapaxar_blue.png

OUR PROJECTS

We are Translating Innovative Research into Novel Therapeutics 

Fighting
Inflammation-Driven Disease

Protease-Activated Receptors (PARs) drive inflammatory responses in kidney disease and other disorders. Preclinical investigations are underway to develop optimal parmodulins to safely treat a range of inflammation-driven diseases.

Function-Therapeutics_Kidneys.png
Pipetting Samples

OUR TEAM

A Seasoned Team to Fight Inflammation-Driven Disease

Function Therapeutics was established based on compounds and assays in the lab of founder Dr. Chris Dockendorff, complemented by research from collaborators including those at Harvard Medical School, Leipzig University, Versiti Blood Research Institute, and the Medical College of Wisconsin. Our executive team and advisors have decades of experience in medicinal chemistry, pharmacology, drug development, and PAR biology.

woman dialysis.jpg

Impact in Numbers

698 million

Cases of chronic kidney disease recorded in 2017 (1)

50%

Of cardiac surgery patients in a retrospective study possessed criteria of acute kidney injury (2)

1 in 5

Deaths worldwide are directly caused by sepsis (4)

1.2 million

Estimated deaths from chronic kidney disease in 2017 (1)

4x

Higher risk of mortality within 90 days of acute kidney injury after bypass surgery (3)

30%

Estimated severe sepsis mortality rate (5)

0

Current drugs for chronic kidney disease able to reverse renal damage

0

FDA-approved drugs to prevent acute kidney injury

0

FDA-approved drugs for sepsis

bottom of page